Search results
Exelixis director Jack Wyszomierski sells shares worth over $180k By Investing.com
Investing.com· 1 hour agoExelixis, Inc. (NASDAQ:EXEL) director Jack L. Wyszomierski has sold 8,287 shares of the company’s...
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In...
Benzinga· 1 day agogeneric versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on...
Pharma stock jumps 8% after company filed its first drug to treat blood volume loss with USFDA
Investing.com· 2 days agoPharma stock engaged in the business of manufacturing, sale, and research and development of generic...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 2 days agoTeva also faces competitive pressure for some of its key branded drugs. The orphan drug exclusivity...
CSPC Pharma Weighs Up Diet Drug For Bigger Bottom Line - CSPC Pharma Gr (OTC:CSPCY), Novo Nordisk...
Benzinga· 1 day agoIt can already fill pharmacy shelves with a wide range of approved drugs for the treatment of...
Marc Crossman Sells 56,235 Shares of PLBY Group, Inc. (NASDAQ:PLBY) Stock
ETF DAILY NEWS· 7 days agoPLBY Group, Inc. (NASDAQ:PLBY – Get Free Report) CFO Marc Crossman sold 56,235 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at ...
Ani Pharmaceuticals CFO sells shares worth over $317k By Investing.com
Investing.com· 14 hours agoCarey. According to the latest filing, Carey sold 5,000 shares of the company's common stock....
2 Stocks to Watch & One to Avoid From the Volatile Retail Pharmacy Industry
Zacks via Yahoo Finance· 1 day agoZacks Retail-Pharmacies and Drug Stores industry players like WBA and HLF are likely to gain despite...
7 F-Rated Stocks to Avoid at All Costs in June
InvestorPlace· 15 hours agoNo tool is infallible, but I’ve found the Portfolio Grader to be an ideal system to help investors of all stripes ferret out which stocks are worth your...
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
Motley Fool via Yahoo Finance· 4 days agoPatent protections should keep generic competition away from Eliquis until at least 2028, and...
